Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 14/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064496 | 0.87 | ELANE (0.38) | ELANECCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2064707 | 0.86 | ELANE (0.43) | ELANECCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL2064415 | 0.83 | BTK (0.35) | ELANERORCHTR6KDM4E | |
| SCHEMBL2064888 | 0.74 | HTR6 (0.45) | MEN1KMT2AHTR6 | |
| SCHEMBL7499179 | 0.74 | ALK (0.35) | RORCHTR6 | |
| SCHEMBL2065324 | 0.73 | HTR6 (0.45) | CCNB2CDK1CCNB1CCNB3HTR6 | |
| SCHEMBL2064302 | 0.72 | HTR6 (0.59) | CCNB2CDK1CCNB1CCNB3MEN1 | |
| SCHEMBL2063442 | 0.72 | L3MBTL1 (0.42) | CCNB2CDK1CCNB1CCNB3HTR6 | |
| SCHEMBL2064275 | 0.71 | HTR6 (0.44) | HTR6KDM4E | |
| SCHEMBL2063435 | 0.70 | BTK (0.38) | ELANEMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148394-B2 | Azaindoles having serotonin receptor affinity | NPS PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-07-08 | — | — | US | claimed |
| EP-1204662-B1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP (CA) | 2004-06-02 | — | — | EP | claimed |
| EP-1204662-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS Allelix Corp. (CA) | 2002-05-15 | — | — | EP | claimed |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | ALLELIX BIOPHARMACEUTICALS, INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001012629-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP. (US) | 2001-02-22 | — | — | WO | claimed |
| US-6191141-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEN DISORDERS | NPS ALLELIX CORP. (CA) | 2001-02-20 | — | — | US | claimed |
| US-20120302596-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8148394-B2 | Azaindoles having serotonin receptor affinity | NPS PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20080004307-A1 | Azaindoles Having Serotonin Receptor Affinity | NPS ALLELIX CORP. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-7268127-B2 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP (CA) | 2007-09-11 | — | — | US | disclosed |
| US-20050239788-A1 | Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor | NPS ALLELIX CORP. (CA) | 2005-10-27 | — | — | US | disclosed |
| US-6916818-B2 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2005-07-12 | — | — | US | disclosed |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-07-08 | — | — | US | disclosed |
| EP-1204662-B1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP (CA) | 2004-06-02 | — | — | EP | disclosed |
| US-6686374-B1 | Azaindoles having serotonin receptor affinity | NPS ALLELIX CORP. (CA) | 2004-02-03 | — | — | US | disclosed |
| EP-1204662-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS Allelix Corp. (CA) | 2002-05-15 | — | — | EP | disclosed |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | ALLELIX BIOPHARMACEUTICALS, INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001012629-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | NPS ALLELIX CORP. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6191141-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEN DISORDERS | NPS ALLELIX CORP. (CA) | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302596-A1 | AZAINDOLES HAVING SEROTONIN RECEPTOR AFFINITY | HTR6, DRD2, HTR1A | ELANE 3679/4885CCNB2 1753/4885CDK1 1992/4885 |
| US-20080004307-A1 | Azaindoles Having Serotonin Receptor Affinity | HTR6, DRD2, HTR1A | ELANE 3679/4885CCNB2 1753/4885CDK1 1992/4885 |
| US-20040132734-A1 | Azaindoles having serotonin receptor affinity | DRD2, HTR3C, HTR2C | ELANE 3752/4885CCNB2 2473/4885CDK1 3115/4885 |
| US-20010049441-A1 | Azaindoles having serotonin receptor affnity | DRD2, DRD3, HTR3C | ELANE 2615/4885CCNB2 3801/4885CDK1 4079/4885 |
| US-20050239788-A1 | Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor | CRHR1, HTR6, HTR1A | ELANE 4315/4885CCNB2 1756/4885CDK1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.